Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs.
The most commonly used method to assess intestinal permeability is the measurement of compound flux across a Caco-2 cells monolayer by using Hanks balanced salt solution (HBSS)-like buffers. Nevertheless, lipophilic acid drugs are poorly or not at all soluble in these types of buffers and their adsorption on the transwell plate is commonly observed. To reduce adsorption and increase solubility, permeability assays need to be developed in conditions other than classic conditions for lipophilic compounds. The best model to increase recovery of lipophilic compounds was determined as fasted state simulated intestinal fluid (FaSSIF) in the apical compartment and HBSS with 1% bovine serum albumin (BSA) in basolateral compartment. This model allows a correlation between absorption on Caco-2 cells and absorbed fraction in humans. For 35 compounds, only 2 outliers were observed in the Caco-2 assay using the FaSSIF model. These two outliers were the same outlier compounds as those observed with a classic Caco-2 method. Furthermore, a permeability assay of Pgp substrates evidenced efflux transport in both models and addition of a Pgp inhibitor suppressed Pgp efflux transport. FaSSIF in the apical compartment and HBSS with 1% BSA in the basolateral compartment is the model of choice to predict in vivo absorption for lipophilic acid drugs.
Preclinical Candidate Selection Unit, Laboratoires Fournier a Solvay Pharmaceuticals Company, 21121 Daix, France.
Lina
L
Fossati
Rachel
R
Dechaume
Emmanuel
E
Hardillier
Delphine
D
Chevillon
Colette
C
Prevost
Sébastien
S
Bolze
Nathalie
N
Maubon
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D001693:Biological Transport, Active / Q000187:drug effects; D002021:Buffers; D018938:Caco-2 Cells; D002463:Cell Membrane Permeability / Q000187:drug effects / Q000502:physiology*; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects / Q000502:physiology*; D013058:Mass Spectrometry; D004364:Pharmaceutical Preparations / Q000378:metabolism*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D002021:Buffers; D004364:Pharmaceutical Preparations